82 completed, 15 recruiting, 13 terminated, 8 active not recruiting. 133 Phase 2, 12 Phase 3, 7 Phase 1.
Follow Suppuration: new trials by email Literature Review of Suppuration trials Research Report on Suppuration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity Olatorepatide, Placebo - Hidradenitis Suppurativa | Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 300 | 2026-10-30 | 2026-09-21 |
| Botulinum Toxin Blockade of Neuronal Signals to Immune Cells as a Novel Treatment for Hidradenitis Suppurativa Botulinum Toxin A (Allergan, Inc, Irvine CA), Placebo - Hidradenitis Suppurativa (HS) | Phase 2 | Not yet recruiting | University of Massachusetts, Worcester | 40 | 2026-10-01 | 2026-09-10 |
| Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa Roflumilast 0.3% topical foam - Hidradenitis Suppurativa (HS) | Phase 2 | Recruiting | Harrison Dermatology | 10 | 2026-09-10 | 2026-10-13 |
| A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial) SPY072, Placebo, bimekizumab - Hidradenitis Suppurativa (HS) | Phase 2 | Recruiting | Spyre Therapeutics, Inc. | 150 | 2026-09-01 | 2026-10-19 |
| The Safety and Efficacy of Roflumilast Foam in HS Roflumilast 0.3% topical foam - Hidradenitis Suppurativa (HS) | Phase 2 | Recruiting | Beth Israel Deaconess Medical Center | 20 | 2026-09-01 | 2026-07-09 |
| ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa ORKA-002, Placebo - Hidradenitis Suppurativa (HS) | Phase 2 | Recruiting | Oruka Therapeutics, Inc. | 200 | 2026-08-21 | 2026-10-29 |
| Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses Methylene Blue, Lipid Emulsion, Insertion of optical fiber - Abscess | Phase 2 | Not yet recruiting | University of Rochester | 120 | 2026-07-15 | 2026-02-10 |
| A 24-Week Real-World Study of Upadacitinib in Moderate-to-Severe Hidradenitis Suppurativa Upadacitinib - Hidradenitis Suppurativa (Acne Inversa) | Phase 2 | Active not recruiting | Peking Union Medical College | 50 | 2026-07-01 | 2026-07-27 |
| A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa LAD328, Placebo - Hidradenitis Suppurativa | Phase 2 | Recruiting | Almirall, S.A. | 50 | 2026-05-13 | 2026-08-17 |
| Chemical vs Mechanical Pleural Adhesiolysis for Liberation of Captive Pleura in Stacked Effusion Intrapleural Hydrogen Peroxide (H_2O_2), Intrapleural Corticosteroids, Thoracoscopic Mechanical Pleurolysis - Pleural Infection, Pleural Adhesions | Phase 2 | Completed | Delta University for Science and Technology | 36 | 2026-03-26 | 2026-07-20 |
| Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Povorcitinib - Hidradenitis Suppurativa (HS) | Phase 2 | Recruiting | Incyte Corporation | 40 | 2026-02-02 | 2026-10-09 |
| A Study of Zasocitinib in Adults With Hidradenitis Suppurativa Zasocitinib (Dose A), Placebo - Hidradenitis Suppurativa | Phase 2 | Recruiting | Takeda | 90 | 2026-01-26 | 2026-03-06 |
| A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa NAV-240, Placebo to match NAV-240 - Hidradenitis Suppurativa (HS) | Phase 2 | Recruiting | Navigator Medicines, Inc. | 150 | 2026-01-05 | 2026-07-22 |
| A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa SAR445399, Placebo - Hidradenitis Suppurativa | Phase 2 | Recruiting | Sanofi | 144 | 2025-12-29 | 2026-10-16 |
| Abdominal aBscess Catheter Sclerotherapy (ABCS) Catheter Sclerotherapy - Abdominal Abscess | Phase 1 / Phase 2 | Active not recruiting | University of Alabama at Birmingham | 60 | 2025-12-21 | 2026-09-24 |
| Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa SCT650C - Hidradenitis Suppurativa (HS) | Phase 2 | Recruiting | Sinocelltech Ltd. | 60 | 2025-12-16 | 2026-04-28 |
| A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS. Ritlecitinib, Placebo - Hidradenitis Suppurativa | Phase 2 | Active not recruiting | Pfizer | 128 | 2025-11-13 | 2026-10-20 |
| Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa Brivekimig, Placebo - Hidradenitis Suppurativa | Phase 2 | Recruiting | Sanofi | 208 | 2025-11-06 | 2026-10-14 |
| A Study of LAD191 in Adults With Hidradenitis Suppurativa LAD191, Placebo, Adalimumab - Hidradenitis Suppurativa | Phase 2 | Recruiting | Almirall, S.A. | 200 | 2025-11-05 | 2026-05-11 |
| A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa BFB759, Placebo for BFB759 - Hidradenitis Suppurativa (HS) | Phase 2 / Phase 3 | Active not recruiting | Bluefin Biomedicine, Inc. | 210 | 2025-11-03 | 2026-10-14 |
Showing 20 of 133. Sign in to see all of them.
Hidradenitis Suppurativa (89) · Cellulitis (22) · Abscess (16) · Skin Diseases (12) · Hidradenitis (9) · Wound Infection (6) · Abdominal Abscess (5) · Bacterial Infections (4) · Skin Diseases, Bacterial (4) · Dermatitis, Atopic (3) · Empyema (3) · Empyema, Pleural (3) · Erysipelas (3) · Gram-Positive Bacterial Infections (3) · Periapical Abscess (3)
Infections (131) · Skin and Connective Tissue Diseases (111) · Skin Diseases, Infectious (109) · Bacterial Infections and Mycoses (103) · Bacterial Infections (98) · Skin Diseases, Bacterial (92) · Skin Diseases (86) · Sweat Gland Diseases (86) · Hidradenitis (80) · Pathologic Processes (40) · Pathological Conditions, Signs and Symptoms (40) · Inflammation (36) · Connective Tissue Diseases (22) · Abscess (11)
Adalimumab (6) · Linezolid (5) · Injections (4) · Sodium Chloride (4) · Roflumilast (3) · BDB001 (2) · Dexamethasone (2) · Gentian Violet (2) · Interleukin 1 Receptor Antagonist Protein (2) · Leucovorin (2) · Methylene Blue (2) · Pyrimethamine (2) · Saline Solution (2) · Tissue Plasminogen Activator (2) · Trimethoprim, Sulfamethoxazole Drug Combination (2)
Incyte Corporation (5) · AbbVie (4) · Boehringer Ingelheim (4) · Florida Academic Dermatology Centers (4) · Janssen Research & Development, LLC (4) · Sanofi (4) · Beth Israel Deaconess Medical Center (3) · InflaRx GmbH (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Almirall, S.A. (2) · Cumberland Pharmaceuticals (2) · Eli Lilly and Company (2) · GlaxoSmithKline (2) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2) · Milton S. Hershey Medical Center (2)
United States (88) · Canada (39) · Germany (32) · Spain (25) · Poland (24) · Australia (20) · Netherlands (20) · France (17) · Greece (16) · China (11) · Italy (11) · Bulgaria (9) · Czechia (9) · Denmark (9) · Japan (9)
Baoxi Wang, Master (2) · Evangelos J Giamarellos-Bourboulis, MD, PhD (2) · Francisco A Kerdel, M.D (2) · G. Ralph Corey, MD (2) · Kathleen Butler, MD (2) · Martina Porter, MD (2) · Adam J Singer, MD (1)
PMID 34252397, PMID 34978076, PMID 19185954, PMID 19220646, PMID 20115947, PMID 21537018, PMID 23247938, PMID 23570475, PMID 24010809, PMID 25136015, PMID 25785967, PMID 26579854, PMID 26711777, PMID 27136622, PMID 27530088, PMID 28363363, PMID 28657870, PMID 29380251, PMID 29914924, PMID 32004568, PMID 34406364, PMID 36892753, PMID 37317022, PMID 37522746, PMID 38335032, PMID 38946973, PMID 39737640, PMID 39899371, PMID 39909350, PMID 41061970, PMID 41081529, PMID 41848710
2025 (7), 2023 (3), 2018 (2), 2004 (1), 2008 (1), 2009 (1), 2017 (1), 2019 (1), R33AR077495 (1), R61AR087105 (1)